<DOC>
	<DOC>NCT00583609</DOC>
	<brief_summary>To evaluate the patient acceptance of a new PEG3350 dose formulation in children currently treated with PEG3350 powder for treatment of constipation.</brief_summary>
	<brief_title>A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>Male or female constipated outpatients between the ages of 4 and 16 Currently taking a dose of PEG 3350 powder up to a maximum of 17g per day that has been consistent for at least 4 weeks, or if less than 4 weeks, the investigator testifies that the patient is stable Current treatment is considered successful defined as greater than 2 bowel movements per week with no accidents Are otherwise in good health, as judged by a physical examination If female and of childbearing potential, patient must be using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so for the duration of the study In the investigator's judgment, patient or guardian is mentally competent to sign an instrument of informed consent Patients who are impacted at baseline exam Patients with known or suspected perforation or obstruction Patients with a history of gastric retention, inflammatory bowel disease, bowel resection, or colostomy Patients with a known history of organic cause for their constipation Patients currently using medications known to cause constipation (these include opiates, antidepressants, SSRI's, antimotility agents and anticholinergics) Patients who are breastfeeding, pregnant, or intend to become pregnant during the study Female patients of childbearing potential who refuse a pregnancy test Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedure Patients with known allergy to PEG or PEG containing medications Patients who, within the past 30 days have participated in an investigational clinical study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>